Samsung Bioepis records KRW 314.8 billion sales and continue losses in operating & net profits

Samsung Bioepis(unlisted, subsidiary of Samsung Biologics) achieved KRW 314.8 billion sales last year based on the audit report on March and grew 113.4% up compared to the year before.

The company continued to make negative operating profits of KRW 103.5 billion and negative net profits of KRW 88.3 billion.

Their SG&A(selling, general & administrative) expenses were increased by 41.2%, and th...